SHARP study

Introduction

Study characteristics:

• 9500 adults with chronic kidney disease
• ezetimibe/simvastatin (Vytorin) vs placebo

Outcome:

• incidence of myocardial infarction, cardiac death, stroke, or revascularization over roughly 5 years' follow-up

Results:

• outcomes occured significantly less often in patients randomized to Vytorin than with placebo (3% absolute difference between the groups).
• difference largely due to fewer ischemic strokes & revascularization procedures in Vytorin group
• Vytorin did not increase risk of cancer-related death

Notes

• study does not whether adding ezetimibe to a statin improves outcomes beyond the statin alone

More general terms

• clinical trial